LYFEBULB-HELSINN
CANCER INNOVATION
SUMMIT & AWARD

Lyfebulb-Helsinn Award 2020

Ten finalists will compete at the third annual Lyfebulb-Helsinn Innovation Summit. The Lyfebulb-Helsinn Innovation Award will be presented to an exceptional innovator with outstanding entrepreneurial potential to commercialize a creative idea to better manage cancer using drugs, medical devices or healthcare information technology.

JANUARY 29-30, 2020 | Grimaldi Forum, Monaco

Deadline for applications is November 17, 2019 at 11:59pm EST / November 18, 2019 at 5:59am CEST

THE SUMMIT AND AWARD BENEFITS

10 Selected Patient Entrepreneurs will receive an invitation (and expenses paid trip*) to Monaco in January 2020 to present to and interact with an esteemed jury at the Biennale Monégasque de Cancérologie for a chance to win one of two $25,000 monetary grants


  • The Innovation Summit provides a collaborative setting that brings together Patient Entrepreneurs to spotlight their efforts and exchange ideas on how to further advance patient innovation in the cancer community
  • Finalists will have an opportunity to engage with senior leadership at Lyfebulb and Helsinn, representatives from the patient community, key opinion leaders, and investors / VCs beyond Lyfebulb and Helsinn
  • Two $25,000 awards will be granted at the conclusion of the Summit: The Lyfebulb Helsinn Innovation Award and the Squinto-LePera Award
  • The 10 finalists will benefit from increased visibility on an international scale for their companies’ innovative efforts
  • All competing companies will be considered for possible investment by Helsinn

         *Airfare, hotel and meals will be provided

Summit Agenda

January 29
Registration
Introductory Meetings and Technical Rehearsal
Welcome Dinner
January 30
Guest Presentations
Pitch Presentations
Networking Cocktails
Gala Dinner and Award Ceremony

AWARD & JUDGING CRITERIA

The Lyfebulb-Helsinn Innovation Summit application is open to innovators* currently working on a groundbreaking project, which can advance the prevention, management, or care of cancer, using drugs, medical devices or healthcare information technologies.


The expert judging panel will evaluate pitches based upon:

  • How does the invention/product have the potential to improve the lives of people with cancer?
  • Does it address an unmet market need?
  • Is the product or service unique in the market (not an altered marketed product)?
  • Does the company/product use innovative and effective technologies that are scalable?
  • Can the company/product meet the challenges encountered by healthcare companies (e.g. funding, regulations, requirements for clinical testing, etc.)?

* Finalists from the 2018 or 2019 Lyfebulb-Helsinn Innovation Summit and any parties in whom Helsinn and/or Lyfebulb have a financial interest may not apply.

Driving Change

The Lyfebulb-Helsinn Innovation Summit stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features individuals who have created a product and a company based on issues encountered due to their personal experiences with a chronic illness.

Lyfebulb and Helsinn believe that patient innovators have a unique ability to create a value-added disease intervention beyond therapy. The sponsors are laser-focused on improving the quality of life for those living with cancer.

About Lyfebulb

Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental illness and migraine.

About Helsinn International Services sarl

Helsinn International logo
Helsinn International Services sarl is the Helsinn subsidiary which provides a range of advisory services and strategic activities to the Group and its specific companies. In particular, it acts as the advisory company to Helsinn Investment Fund.

For more information, visit www.helsinninvestmentfund.com

About Helsinn Investment Fund S.A., SICAR

The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.

Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.

For more information, visit www.helsinninvestmentfund.com

About the Helsinn Group

Helsinn is a privately-owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit www.helsinn.com